These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 3551154

  • 21. Hemodynamic effects of intravenous PGE1 on patients with arterial occlusive disease of the leg.
    Hirai M, Nanki M, Nakayama R.
    Angiology; 1985 Jul; 36(7):407-13. PubMed ID: 4040721
    [Abstract] [Full Text] [Related]

  • 22. Prostaglandin E1 therapy for peripheral vascular disease is better than placebo.
    Clin Physiol; 1982 Apr; 2(2):163-5. PubMed ID: 7044658
    [No Abstract] [Full Text] [Related]

  • 23. Intravenous infusion of prostaglandin E1 (PGE1) in management of limb ischemia.
    Sethi GK, Bridgman AH, King L, Scott SM.
    Am Surg; 1986 Sep; 52(9):474-8. PubMed ID: 3752724
    [Abstract] [Full Text] [Related]

  • 24. [Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental--results of a multicenter double-blind study].
    Rudofsky G, Haussler KF, Künkel HP, Schneider-May H, Spengel F, Symann O, Werner HJ, Rössner M.
    Vasa Suppl; 1987 Sep; 20():375-8. PubMed ID: 3321494
    [No Abstract] [Full Text] [Related]

  • 25. [Clinical and instrumental evaluation of patients with chronic peripheral arterial occlusive disease after prolonged administration of suloctidil].
    Gregoratti L, Redaelli G, Limido P, Ghiringhelli L.
    Clin Ter; 1982 Sep 30; 102(6):607-19. PubMed ID: 6291844
    [No Abstract] [Full Text] [Related]

  • 26. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease.
    Gianetti J, De Caterina M, De Cristofaro T, Ungaro B, Guercio RD, De Caterina R.
    Am Heart J; 2001 Oct 30; 142(4):733-9. PubMed ID: 11579367
    [Abstract] [Full Text] [Related]

  • 27. PGE1 in arterial occlusive disease stage III and IV.
    Bruch HP, Hörl M, Schindler G.
    Vasa Suppl; 1987 Oct 30; 17():26-31. PubMed ID: 3470962
    [No Abstract] [Full Text] [Related]

  • 28. [Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].
    Branchereau A, Rouffy J.
    J Mal Vasc; 1995 Oct 30; 20(1):21-7. PubMed ID: 7745355
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study.
    Int Angiol; 1994 Mar 30; 13(1):70-4. PubMed ID: 7521384
    [Abstract] [Full Text] [Related]

  • 30. [Intravenous infusions in the treatment of arterial occlusive diseases from the surgical point of view].
    Hugeneck J.
    Wien Med Wochenschr; 1976 Sep 17; 126(38):542-4. PubMed ID: 788353
    [No Abstract] [Full Text] [Related]

  • 31. [Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial].
    Rossini A, Tascino C, Costa F.
    Minerva Cardioangiol; 1998 Nov 17; 46(11):457-69. PubMed ID: 10207294
    [Abstract] [Full Text] [Related]

  • 32. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
    Eur J Vasc Endovasc Surg; 2000 Oct 17; 20(4):358-62. PubMed ID: 11038148
    [Abstract] [Full Text] [Related]

  • 33. [Intravenous infusion of Naftidrofuryl in the treatment of arterial diseases of the limbs. Clinical and functional study].
    Schmidt C, Royer RJ, Kissel P.
    Therapie; 1974 Oct 17; 29(6):915-23. PubMed ID: 4618388
    [No Abstract] [Full Text] [Related]

  • 34. Peripheral occlusive arterial disease in diabetic clinic attendees.
    Vigilance JE, Reid HL, Richards-George P.
    West Indian Med J; 1999 Sep 17; 48(3):143-6. PubMed ID: 10555462
    [Abstract] [Full Text] [Related]

  • 35. Intravenous prostavasin--therapy in peripheral arterial occlusive disease in Fontaine's stages III and IV. Early and late results of a screening study.
    Heidrich H, Meuche C, Ranft J, Rummel S, Peters A.
    Prog Clin Biol Res; 1989 Sep 17; 301():411-6. PubMed ID: 2678131
    [No Abstract] [Full Text] [Related]

  • 36. Antithrombotic drugs in peripheral obliterative arterial diseases.
    Coccheri S, Palareti G, Fortunato G.
    Haemostasis; 1994 Sep 17; 24(2):118-27. PubMed ID: 7959359
    [Abstract] [Full Text] [Related]

  • 37. Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
    Leschke M, Schoebel FC, Strauer BE.
    Clin Hemorheol Microcirc; 1997 Sep 17; 17(1):59-66. PubMed ID: 9181759
    [Abstract] [Full Text] [Related]

  • 38. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease.
    Darius H, Kopp H, Mulfinger A, Spielberger M, Todt M, Schuster CJ, Meyer J.
    Prog Clin Biol Res; 1989 Sep 17; 301():417-21. PubMed ID: 2508112
    [No Abstract] [Full Text] [Related]

  • 39. Prostaglandin E1 in severe lower limb ischaemia: a double-blind controlled trial.
    Telles GS, Campbell WB, Wood RF, Collin J, Baird RN, Morris PJ.
    Br J Surg; 1984 Jul 17; 71(7):506-8. PubMed ID: 6375799
    [Abstract] [Full Text] [Related]

  • 40. Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD).
    Craveri A, Tornaghi G, Ranieri R, Stanzani M, Landi G, Paganardi L, Passaretti B, Gallo E.
    Int Angiol; 1990 Jul 17; 9(4):274-7. PubMed ID: 2099963
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.